Psilocybin Mushrooms Studies

Psilocybin therapy is an approach being investigated for the treatment of mental health challenges. It combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support.

Psilocybin is an active ingredient in some species of mushrooms, often referred to as ‘magic mushrooms’. We have developed a synthesised formulation of psilocybin, COMP360, and are investigating the effectiveness of psilocybin therapy, initially in treatment-resistant depression.

Early studies conducted in pioneering academic centres have shown signals that psilocybin could be a safe and effective medicine for patients with depression, anxiety, addiction and other mental illnesses, when administered with psychological support from specially-trained therapists.*

In October 2020, Oregon became the first state to legalize psilocybin. This allows for a 2-year period to consider regulatory and prescribing requirements.

Psilocybin is a Schedule I substance, meaning that the Drug Enforcement Administration (DEA) believes it has a high potential for abuse and serves no legitimate medical purpose.

Although medical bodies do not consider psilocybin addictive, users may experience disturbing hallucinations, anxiety, and panic after taking the drug.

Psilocybin is a hallucinogenic chemical in certain mushrooms known as magic mushrooms. Eating mushrooms that contain psilocybin can have a variety of effects, ranging from euphoria to hallucinations.

Individuals use psilocybin as a recreational drug. It can provide feelings of euphoria and sensory distortion that are common to hallucinogenic drugs, such as LSD.

Researchers at Johns Hopkins Center for Psychedelic and Consciousness Research published a landmark studyTrusted Source on the safety and positive effects of psilocybin. Researchers have also investigated whether it may be used to treat various medical conditions.

In October 2020, Oregon became the first state to legalize psilocybin. This allows for a 2-year period to consider regulatory and prescribing requirements.

Psilocybin is a Schedule I substance, meaning that the Drug Enforcement Administration (DEA) believes it has a high potential for abuse and serves no legitimate medical purpose.

Although medical bodies do not consider psilocybin addictive, users may experience disturbing hallucinations, anxiety, and panic after taking the drug.

Fast facts on psilocybin

• Psilocybin can have both positive and negative physical and psychological effects.
• Psilocybin is not naturally addictive.
• The drug can trigger psychotic episodes.
• Individuals with a family history of psychosis face an increased risk of an adverse psychiatric reaction to psilocybin.

_{*Ross et al, 2023; Griffiths et al, 2023; Carhart-Harris et al, 2023}

‍

_{Informational blog system only:}

_{I AM NOT PROVIDING THIS TREATMENT AT CURRENT TIME. Jorge Garcia PMHNP-BC}

_‍